Equities

Immatics NV

Immatics NV

Actions
  • Price (USD)13.61
  • Today's Change-1.03 / -7.04%
  • Shares traded197.96k
  • 1 Year change+48.10%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2021 21:00 BST.
More ▼
Take Survey
Help shape our future virtual events & community services
Take part in our survey for a chance to win a free 3-month standard gift subscription.

Profile data is unavailable for this security.

About the company

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

  • Revenue in USD (TTM)45.32m
  • Net income in USD-290.42m
  • Incorporated--
  • Employees142.00
  • Location
    Immatics NVPaul Ehrlich-Strasse 15TUEBINGEN 72076GermanyDEU
  • Phone+49 70 715397700
  • Websitehttps://immatics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BioXcel Therapeutics Inc0.00-99.83m858.65m50.00--3.21-----4.12-4.120.009.560.00----0.00-56.79-73.75-61.82-83.24------------0.00-------149.24--216.18--
Akero Therapeutics Inc0.00-95.14m867.71m28.00--3.94-----2.75-2.750.006.320.00----0.00-54.04---58.51--------------0.00-------81.02------
Phibro Animal Health Corp833.35m54.39m876.90m1.73k16.123.6810.161.051.341.3420.575.891.032.726.10483,101.406.697.778.349.7232.5632.336.536.781.728.910.621832.564.122.0962.09-8.05-4.213.71
Crinetics Pharmaceuticals Inc0.00-88.96m879.25m93.00--4.26-----2.61-2.610.005.350.00----0.00-40.99---43.16--------------0.00---94.05---46.39------
Amphastar Pharmaceuticals Inc384.04m10.45m882.34m1.98k87.052.0924.912.300.2110.2117.738.790.60682.166.52193,957.101.832.192.422.7543.1439.463.023.721.71--0.07620.008.536.82-97.13--18.62--
Praxis Precision Medicines Inc0.00-110.59m892.46m67.00--2.67-----2.79-2.790.007.470.00----0.00-56.20---60.02--------------0.00-------72.86------
Beyondspring Inc856.00k-68.43m896.13m91.00--16.21--1,046.88-1.93-1.930.02411.410.0132----9,406.59-109.70-165.62-142.64-226.45-----8,282.36-150,311.70----0.0364-------60.10--5.39--
Sutro Biopharma Inc68.81m-78.92m908.18m204.00--2.95--13.20-1.82-1.821.626.660.2159--9.65360,261.80-24.76---27.41-------114.69-----4.390.0747---0.0328--42.37------
Immatics NV45.32m-290.42m920.98m142.00--8.38--20.32-4.58-4.580.75011.750.2071----319,183.70-133.00---164.76-------642.20-----15.890.0635--69.40---625.54------
Stoke Therapeutics Inc0.00-67.01m927.55m79.00--3.63-----1.88-1.880.006.950.00----0.00-28.23---29.09--------------0.00-------61.62------
4D Molecular Therapeutics Inc-100.00bn-100.00bn939.19m104.00--3.89----------8.95----------------------------0.00--94.85---14.98------
Alterola Biotech Inc0.00-620.31k950.39m0.00---------0.0029-0.00290.00-0.00120.00-------4,067.61----------------------------------
Singular Genomics Systems Inc0.00-77.25m958.14m169.00--2.61-----1.10-1.100.005.13------0.00-------------------1.120.0254-------126.75------
Syndax Pharmaceuticals Inc1.52m-91.49m962.83m43.00--4.49--635.11-1.89-1.890.03144.410.0067--4.6335,255.81-40.16-52.37-43.68-59.73-----6,035.16-3,914.71---44.250.0866--0.0019.33-37.50------
OraSure Technologies, Inc.227.06m5.31m963.48m570.00182.942.3863.224.240.07310.07313.145.620.51262.367.42398,342.101.203.691.314.1060.5561.872.346.865.0919.470.00640.0011.077.48-189.59--50.52--
Glucose Health Inc88.13k-85.06k984.08m2.00------11,166.24-0.0282-0.02820.0243-0.09442.51--8.45---241.96-751.92----65.395.48-96.52-999.86---0.293----7,235.60---54.27------
Data as of Sep 20 2021. Currency figures normalised to Immatics NV's reporting currency: US Dollar USD

Institutional shareholders

28.55%Per cent of shares held by top holders
HolderShares% Held
Baker Bros. Advisors LPas of 30 Jun 20214.28m6.81%
Nantahala Capital Management LLCas of 30 Jun 20212.54m4.05%
Perceptive Advisors LLCas of 30 Jun 20212.50m3.97%
Alyeska Investment Group LPas of 30 Jun 20212.15m3.42%
Redmile Group LLCas of 30 Jun 20211.94m3.09%
Federated Global Investment Management Corp.as of 30 Jun 20211.76m2.79%
683 Capital Management LLCas of 30 Jun 20211.18m1.88%
University of Texas Investment Management Co.as of 30 Jun 2021697.43k1.11%
Woodline Partners LPas of 30 Jun 2021548.93k0.87%
RTW Investments LPas of 30 Jun 2021350.00k0.56%
More ▼
Data from 30 Jun 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
image